Detailed information for compound 456014

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 342.515 | Formula: C23H34O2
  • H donors: 2 H acceptors: 2 LogP: 4.54 Rotable bonds: 3
    Rule of 5 violations (Lipinski): 1
  • SMILES: C=CC[C@H]1[C@@H](O)CC[C@]2(C1=CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2O)C)C=C
  • InChi: 1S/C23H34O2/c1-4-6-16-18-8-7-15-17-9-10-21(25)22(17,3)13-11-19(15)23(18,5-2)14-12-20(16)24/h4-5,8,15-17,19-21,24-25H,1-2,6-7,9-14H2,3H3/t15-,16+,17-,19-,20-,21-,22-,23-/m0/s1
  • InChiKey: FFAZSAAUQAPBJT-NJRYMHDPSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens estrogen receptor 2 (ER beta) Starlite/ChEMBL References
Homo sapiens androgen receptor Starlite/ChEMBL References
Homo sapiens estrogen receptor 1 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Loa Loa (eye worm) hypothetical protein estrogen receptor 2 (ER beta) 495 aa 418 aa 25.8 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Mycobacterium ulcerans 3-dehydroquinate dehydratase 0.1308 0.5 0.5
Mycobacterium tuberculosis 3-dehydroquinate dehydratase AroD (AROQ) (3-dehydroquinase) (type II dhqase) 0.1308 0.5 0.5

Activities

Activity type Activity value Assay description Source Reference
EC50 (functional) > 1000 nM Agonist activity at human recombinant ERalpha expressed in HEK293 cells by transactivation assay ChEMBL. 17448656
EC50 (functional) > 1000 nM Agonist activity at human recombinant ERbeta expressed in HEK293 cells by transactivation assay ChEMBL. 17448656
EC50 (functional) > 1000 nM Agonist activity at human recombinant ERalpha expressed in HEK293 cells by transactivation assay ChEMBL. 17448656
EC50 (functional) > 1000 nM Agonist activity at human recombinant ERbeta expressed in HEK293 cells by transactivation assay ChEMBL. 17448656
IC50 (binding) = 15 nM Binding affinity to androgen receptor ChEMBL. 17448656
IC50 (binding) = 15 nM Binding affinity to androgen receptor ChEMBL. 17448656
IC50 (binding) = 3020 nM Binding affinity to human recombinant ERbeta by scintillation proximity assay ChEMBL. 17448656
IC50 (binding) = 3020 nM Binding affinity to human recombinant ERbeta by scintillation proximity assay ChEMBL. 17448656
IC50 (binding) > 10000 nM Binding affinity to human recombinant ERalpha by scintillation proximity assay ChEMBL. 17448656
IC50 (binding) > 10000 nM Binding affinity to human recombinant ERalpha by scintillation proximity assay ChEMBL. 17448656
Ratio IC50 (binding) = 0.005 Ratio of IC50 for androgen receptor to IC50 for human ERbeta ChEMBL. 17448656
Ratio IC50 (binding) = 1 Ratio of EC50 for human ERalpha to EC50 for human ERbeta ChEMBL. 17448656
Ratio IC50 (binding) > 3 Ratio of IC50 for human ERalpha to IC50 for human ERbeta ChEMBL. 17448656

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.